June 30, 2023 02:21 PM EDTUpdated 03:59 PM

Following controversy, new Biogen director Susan Langer won fewest votes from shareholders

Kyle LaHucik

Senior Reporter

After her controversial nomination by Alex Denner to Biogen’s board, Susan Langer was elected this week with fewer votes than any other member of the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Following controversy, new Biogen director Susan Langer won fewest votes from shareholders

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Pharma's wins and losses in Trump's sprawling executive order on drug prices

US drugs rely heavily on ingredients made overseas, new report shows

Netherlands pours $1.5B into biotech in pursuit of global leadership ambitions

Eli Lilly reports first Phase 3 data for oral GLP-1, posting a win in diabetes

Sanofi to pay $125M upfront for two immunology drugs from little-known biotech

New York-based partnership sets the standard for expanding clinical trial access for underserved and diverse ...

Fol­low­ing con­tro­ver­sy, new Bio­gen di­rec­tor Su­san Langer won fewest votes from share­hold­ers

Senior Reporter

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Following controversy, new Biogen director Susan Langer won fewest votes from shareholders